Dr. B Notes 090613 do gel extractin on PCR squared crystal structures don't have Glutathione nor NADPH (they do have FAD) What is the role of FAD - is it needed for catalysis, or is it just a 'space filler'/crystallization reagent. How can we get NADPH in the active site for docking? How can we define the Glutathione area for docking?
*Target (protein/gene name): P. falciparum 3D7, glutathione reductase *NCBI Gene # or RefSeq#: AF027825.1 *Protein ID (NP or XP #) or Wolbachia#: AAB84117.1 *Organism (including strain): Plasmodium falciparum *Etiologic Risk Group (see link below): Risk Group 2 (RG2) - Parasitic Agents *Background/Disease Information (sort of like the Intro to your Mini Research Write up):
Plasmodium falciparum is a protozoan parasite, one of the species of Plasmodium that cause malaria in humans. It is transmitted by the female Anopheles mosquito. Also, Plasmodium falciparum is the most deadly of the five Plasmodium species. Malaria has a massive impact on human health; it is the world’s second biggest killer after tuberculosis. Around 300 million clinical cases occur each year resulting in between 1.5 - 2.7 million deaths annually, the majority in sub-saharan Africa. It is estimated that 3,000 children under the age of five years fall victim to malaria each day. Around 40% of the world’s population is at risk. Malaria caused by this species (also called malignant or falciparum malaria) is the most dangerous form of malaria, with the highest rates of complications and mortality Almost every malarial death is caused by P. falciparum.
*Essentiality of this protein: Protein is essential Gene/Ortholog: mtu2902 (OG4_10249); Phenotype: essential; Source study: nmpdr Gene/Ortholog: eco3379 (OG4_10249); Phenotype: essential; Source study: gerdes Gene/Ortholog: Tb927.10.10390 (OG4_10249); Phenotype: significant loss of fitness in bloodstream forms (6 days); Source study: alsford Gene/Ortholog: Tb927.10.10390 (OG4_10249); Phenotype: significant loss of fitness in differentiation of procyclic to bloodstream forms; Source studyalsford
*Complex of proteins?: Works alone *Druggable Target: Yes *EC#: 1.8.1.7 *Link to BRENDA EC# page: http://www.brenda-enzymes.org/php/result_flat.php4?ecno=1.8.1.7
Figure1. Reaction catalyzed by glutathione-disulfide reductase
*Structure Available (PDB or Homology model)
-- PDB # or closest PDB entry if using homology model: 3SQP
*Current Inhibitors:25 *Expression Information (has it been expressed in bacterial cells): Possible to express using E.coli http://www.sciencedirect.com/science/article/pii/S0022283603003474?np=y *Purification Method:
Glutathione reductase (E.C.1.8.1.7) was purified from Phaeodactylum tricornutum cells grown axenically in an autotrophic medium. The overall procedure started with preparation of the cell extract and addition of ammonium sulfate to 20% saturation, followed by anion exchange and affinity interaction chromatography (Blue-A- and 2’,5’-ADP-Sepharose). http://www.sciencedirect.com/science/article/pii/S1434461009000479
*Image of protein (PyMol with features delineated and shown separately):
Figure2. Image of 1ONF in PyMol shown as sticks
Figure3. Cartoon form of 1ONF
*Amino Acid Sequence (paste as text only - not as screenshot or as 'code'): >gi|2599403|gb|AAB84117.1| glutathione reductase [Plasmodium falciparum] MVYDLIVIGGGSGGMAAARRAARHNAKVALVEKSRLGGTCVNVGCVPKKIMFNAASVHDILENSRHYGFD TKFSFNLPLLVERRDKYIQRLNNIYRQNLSKDKVDLYEGTASFLSENRILIKGTKDNNNKDNGPLNEEIL EGRNILIAVGNKPVFPPVKGIENTISSDEFFNIKESKKIGIVGSGYIAVELINVIKRLGIDSYIFARGNR ILRKFDESVINVLENDMKKNNINIVTFADVVEIKKVSDKNLSIHLSDGRIYEHFDHVIYCVGRSPDTENL
*length of your protein in Amino Acids: 500 Molecular Weight of your protein in kiloDaltons using the Expasy ProtParam website: 56419.9 Molar Extinction coefficient of your protein at 280 nm wavelength:
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water.
Ext. coefficient 34185
Abs 0.1% (=1 g/l) 0.606, assuming all pairs of Cys residues form cystines
Ext. coefficient 33810
Abs 0.1% (=1 g/l) 0.599, assuming all Cys residues are reduced
do gel extractin on PCR squared
crystal structures don't have Glutathione nor NADPH (they do have FAD)
What is the role of FAD - is it needed for catalysis, or is it just a 'space filler'/crystallization reagent.
How can we get NADPH in the active site for docking?
How can we define the Glutathione area for docking?
*Target (protein/gene name): P. falciparum 3D7, glutathione reductase
*NCBI Gene # or RefSeq#: AF027825.1
*Protein ID (NP or XP #) or Wolbachia#: AAB84117.1
*Organism (including strain): Plasmodium falciparum
*Etiologic Risk Group (see link below): Risk Group 2 (RG2) - Parasitic Agents
*Background/Disease Information (sort of like the Intro to your Mini Research Write up):
Plasmodium falciparum is a protozoan parasite, one of the species of Plasmodium that cause malaria in humans. It is transmitted by the female Anopheles mosquito. Also, Plasmodium falciparum is the most deadly of the five Plasmodium species. Malaria has a massive impact on human health; it is the world’s second biggest killer after tuberculosis. Around 300 million clinical cases occur each year resulting in between 1.5 - 2.7 million deaths annually, the majority in sub-saharan Africa. It is estimated that 3,000 children under the age of five years fall victim to malaria each day. Around 40% of the world’s population is at risk. Malaria caused by this species (also called malignant or falciparum malaria) is the most dangerous form of malaria, with the highest rates of complications and mortality Almost every malarial death is caused by P. falciparum.
TDR Targets Link:
http://www.tdrtargets.org/targets/view?gene_id=2524
*Essentiality of this protein: Protein is essential
Gene/Ortholog: mtu2902 (OG4_10249); Phenotype: essential; Source study: nmpdr
Gene/Ortholog: eco3379 (OG4_10249); Phenotype: essential; Source study: gerdes
Gene/Ortholog: Tb927.10.10390 (OG4_10249); Phenotype: significant loss of fitness in bloodstream forms (6 days); Source study: alsford
Gene/Ortholog: Tb927.10.10390 (OG4_10249); Phenotype: significant loss of fitness in differentiation of procyclic to bloodstream forms; Source studyalsford
*Complex of proteins?: Works alone
*Druggable Target: Yes
*EC#: 1.8.1.7
*Link to BRENDA EC# page:
http://www.brenda-enzymes.org/php/result_flat.php4?ecno=1.8.1.7
*Enzyme Assay information (spectrophotometric, coupled assay ?, reagents):
-- link to Sigma (or other company) page for assay or assay reagents (substrates)
http://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Enzyme_Assay/glutathionereductase.pdf
-- link (or citation) to paper that contains assay information
http://www.ncbi.nlm.nih.gov/pubmed/11705998
-- List cost and quantity of substrate reagents and supplier
GRSA-1KT $579.00 per pack (this is the whole kit - not needed)
http://www.sigmaaldrich.com/catalog/search?interface=All&term=glutathione+reductase&lang=en®ion=US&focus=product&N=0+220003048+219853269+219853286&mode=match%20partialmax
G4626 Sigma - glutathione
http://www.sigmaaldrich.com/catalog/product/sigma/g4626?lang=en®ion=US
*Structure Available (PDB or Homology model)
-- PDB # or closest PDB entry if using homology model: 3SQP
*Current Inhibitors:25
*Expression Information (has it been expressed in bacterial cells):
Possible to express using E.coli
http://www.sciencedirect.com/science/article/pii/S0022283603003474?np=y
*Purification Method:
Glutathione reductase (E.C.1.8.1.7) was purified from Phaeodactylum tricornutum cells grown axenically in an autotrophic medium. The overall procedure started with preparation of the cell extract and addition of ammonium sulfate to 20% saturation, followed by anion exchange and affinity interaction chromatography (Blue-A- and 2’,5’-ADP-Sepharose).
http://www.sciencedirect.com/science/article/pii/S1434461009000479
*Image of protein (PyMol with features delineated and shown separately):
*Amino Acid Sequence (paste as text only - not as screenshot or as 'code'):
>gi|2599403|gb|AAB84117.1| glutathione reductase [Plasmodium falciparum]
MVYDLIVIGGGSGGMAAARRAARHNAKVALVEKSRLGGTCVNVGCVPKKIMFNAASVHDILENSRHYGFD
TKFSFNLPLLVERRDKYIQRLNNIYRQNLSKDKVDLYEGTASFLSENRILIKGTKDNNNKDNGPLNEEIL
EGRNILIAVGNKPVFPPVKGIENTISSDEFFNIKESKKIGIVGSGYIAVELINVIKRLGIDSYIFARGNR
ILRKFDESVINVLENDMKKNNINIVTFADVVEIKKVSDKNLSIHLSDGRIYEHFDHVIYCVGRSPDTENL
VQLTPVAINAGRLLADRLFLKKTRKTNYKLIPTVIFSHPPIGTIGLSEEAAIQIYGKENVKIYESKFTNL
FFSVYDIEPELKEKTYLKLVCVGKDELIKGLHIIGLNADEIVQGFAVALKMNATKKDFDETIPIHPTAAE
EFLTLQPWMK
*length of your protein in Amino Acids: 500
Molecular Weight of your protein in kiloDaltons using the Expasy ProtParam website: 56419.9
Molar Extinction coefficient of your protein at 280 nm wavelength:
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water.
- Ext. coefficient 34185
- Abs 0.1% (=1 g/l) 0.606, assuming all pairs of Cys residues form cystines
- Ext. coefficient 33810
- Abs 0.1% (=1 g/l) 0.599, assuming all Cys residues are reduced
TMpred graph Image (http://www.ch.embnet.org/software/TMPRED_form.html). Input your amino acid sequence to it.*CDS Gene Sequence (paste as text only):
>gi|2599402|gb|AF027825.1| Plasmodium falciparum glutathione reductase (GR3) mRNA, complete cds
AAAGTTTTTTTTTTTTTTTTTCTTATAAAACTTATTAATTATGTACAAACATAGATACTTTCATTTTTTT
TCTTTTTCTTTTTTTTTCTCGTGTCAACCAAAATAATAAGAAGTTTTACTTTTCTTAACAATAATACAAA
TTTGAGTAATCCAGTATACTTTAAAAAAAACGCAAATATGGTTTACGATTTAATTGTAATTGGTGGTGGA
AGTGGAGGAATGGCTGCAGCTAGGAGGGCAGCAAGGCATAACGCAAAAGTTGCTCTTGTCGAAAAATCCC
GTTTAGGTGGAACGTGTGTCAACGTTGGATGTGTTCCTAAAAAAATTATGTTCAATGCTGCCTCAGTTCA
TGATATTTTGGAAAATTCCAGGCATTACGGATTTGACACCAAATTTTCGTTCAACTTACCTCTGTTGGTA
GAGAGAAGGGATAAGTACATTCAAAGGTTGAATAATATTTATAGACAGAATTTAAGTAAGGATAAGGTAG
ATTTGTACGAAGGAACAGCTAGCTTTTTAAGCGAAAATAGGATATTAATAAAAGGCACAAAAGATAATAA
TAATAAGGATAATGGGCCTTTGAATGAAGAAATCCTTGAAGGAAGAAATATTCTTATAGCTGTTGGAAAT
AAACCAGTATTTCCACCGGTTAAAGGTATAGAAAATACAATATCAAGTGATGAATTTTTTAATATTAAAG
AATCTAAAAAAATTGGTATTGTTGGAAGTGGATATATAGCTGTTGAATTAATAAATGTTATAAAAAGATT
AGGTATTGATTCTTATATATTTGCAAGAGGAAATAGAATATTAAGGAAATTTGATGAGTCTGTTATTAAT
GTATTAGAAAATGATATGAAAAAGAATAATATAAATATTGTAACATTTGCAGATGTTGTTGAAATAAAAA
AAGTTAGTGATAAAAATTTGTCCATACATTTATCTGATGGAAGAATATATGAACATTTTGATCATGTCAT
TTATTGTGTTGGTAGATCACCAGATACCGAAAATTTAAATTTAGGAAAATTAAATGTGGAAACAAATAAT
AATTATATAGTAGTAGATGAAAATCAACGAACTAGTGTAAACAATATTTATGCTGTTGGTGATTGTTGTA
TGGTAAAAAAATCAAAAGAAATTGAAGATTTAAATTTATTGAAATTATATAATGAAGAAACATATCTAAA
TAAAAAAGAAAATGTTACAGAAGATATTTTTTATAATGTACAATTAACACCGGTAGCTATTAATGCAGGA
AGATTATTAGCTGATAGATTATTTTTAAAAAAAACACGAAAAACAAATTATAAACTTATACCAACTGTTA
TATTTTCTCATCCACCTATAGGTACTATTGGTCTTTCTGAAGAAGCAGCAATTCAAATATATGGAAAGGA
AAATGTTAAAATATATGAATCCAAATTTACTAATTTATTCTTTTCAGTTTATGATATAGAACCAGAACTA
AAAGAAAAAACATATCTTAAATTAGTATGTGTTGGAAAAGATGAATTAATTAAAGGATTACATATAATAG
GATTAAATGCAGATGAAATTGTTCAAGGTTTTGCAGTGGCCTTAAAAATGAATGCTACCAAAAAGGATTT
CGATGAAACCATACCTATACATCCTACAGCAGCAGAAGAATTTCTAACCTTACAGCCATGGATGAAATGA
GTTCTCTCTTGAATAACTTCTTCACATAGGATTGTGTATATGTAATATATTAATATATATTAATAAATAA
TTAGTATATCATGCGTTTAAGCTGGCATATCTTAAAAGTTGTATAAATATCATATACAAGCGCGCGCGCG
CCCATACATACATACATAAATAAATATATATATATATTAATTTATTTTATTAGAACACCTTATGTTTCCT
AGCTATAATTCATATTACCCTTTAATCGTATTTATTTTTTTATTTTTTTATTTTTTTTATTTCTTTTTAA
TATTCTTCAAACCATTATAGTAAACCTACATATCCTTTCACATTTATACTCAAAGTGGTACCTTGTGAAT
TTTTATTTTTATTTTTTAAATCAACACATATACTACAATAAATTGTAAAAACTTTATAATATTAAATATT
TTATTTATTTTTAAAAAAAAAAAAAAAA
*GC% Content for gene: 25.8%
*CDS Gene Sequence (codon optimized) - copy from output of Primer Design Protocol (paste as text only):
1 ATGGTCTACGATCTGATTGTAATTGGTGGTGGCTCTGGTGGTATGGCGGCTGCACGCCGT
61 GCCGCACGTCACAACGCGAAAGTTGCACTGGTTGAAAAATCCCGTCTGGGTGGTACCTGT
121 GTGAACGTGGGCTGCGTGCCGAAAAAGATCATGTTCAATGCGGCGTCTGTTCATGACATC
181 CTCGAGAACTCTCGCCACTATGGTTTTGATACGAAATTCTCCTTCAATCTCCCACTGCTG
241 GTCGAACGTCGTGACAAATACATCCAGCGTCTCAACAACATTTATCGCCAGAACCTCTCT
301 AAAGACAAGGTTGACCTGTACGAAGGCACCGCGTCTTTCCTCTCTGAAAACCGTATTCTG
361 ATTAAAGGTACGAAAGATAATAACAACAAGGACAATGGTCCGCTGAACGAGGAAATCCTG
421 GAAGGTCGTAACATCCTGATCGCGGTCGGTAACAAACCTGTTTTCCCACCGGTAAAAGGT
481 ATCGAAAACACCATCAGCAGCGACGAGTTCTTCAACATCAAGGAATCCAAGAAAATCGGT
541 ATCGTTGGTAGCGGTTATATCGCAGTCGAACTGATCAACGTGATCAAACGCCTCGGTATT
601 GACTCTTACATCTTCGCGCGTGGTAACCGCATTCTGCGTAAGTTTGACGAGTCTGTCATC
661 AATGTTCTGGAAAATGATATGAAGAAGAATAACATTAACATCGTTACCTTCGCGGACGTT
721 GTAGAAATCAAGAAAGTCTCTGACAAAAATCTGTCTATTCACCTGAGCGACGGTCGCATC
781 TATGAACACTTTGACCACGTCATTTACTGCGTCGGTCGTTCCCCGGATACTGAGAATCTC
841 AACCTCGAAAAACTGAACGTTGAAACGAACAATAACTATATCGTGGTCGACGAGAACCAG
901 CGTACGTCCGTAAACAATATCTATGCGGTAGGCGACTGCTGCATGGTTAAAAAGTCTAAG
961 GAGATCGAAGACCTGAATCTGCTCAAGCTGTACAACGAAGAGACGTATCTGAACAAAAAA
1021 GAGAACGTCACCGAGGACATCTTTTACAATGTCCAGCTGACCCCAGTTGCCATCAACGCG
1081 GGTCGTCTGCTGGCGGATCGCCTCTTCCTGAAAAAAACCCGTAAGACCAACTACAAGCTG
1141 ATTCCAACCGTGATTTTTAGCCACCCGCCAATCGGCACTATTGGTCTGTCTGAGGAAGCT
1201 GCGATCCAGATCTACGGTAAAGAAAACGTTAAAATCTACGAATCTAAATTCACCAACCTC
1261 TTCTTTTCTGTTTATGACATTGAGCCGGAGCTGAAGGAAAAGACCTACCTGAAGCTGGTT
1321 TGTGTTGGCAAAGACGAACTCATTAAGGGTCTGCACATCATCGGTCTGAACGCCGACGAA
1381 ATCGTTCAAGGTTTCGCCGTGGCGCTCAAGATGAACGCGACGAAGAAGGACTTCGATGAA
1441 ACCATCCCGATCCACCCGACGGCGGCAGAAGAGTTCCTCACTCTGCAGCCATGGATGAAA
1501 TAA
*GC% Content for gene (codon optimized): 47%
Do Not Need this info for Spring (but still copy these lines to your Target page for now)
Primer design results for pNIC-Bsa4 cloning (list seqeunces of all of your ~40 nt long primers):
(link to DNA Works output text file - that should be saved in your Google Docs folder after you did the primer design protocol)
-- Ask a mentor, Dr. B, or a fellow researcher -how to link a GDocs file if you are not sure how to.
1 ATGGTCTACGATCTGATTGTAATTGGTGGTGGCTCTGGTGGTATGGCGGCTGCACGC 57
2 GGGATTTTTCAACCAGTGCAACTTTCGCGTTGTGACGTGCGGCACGGCGTGCAGCCGCCA 60
3 TTGCACTGGTTGAAAAATCCCGTCTGGGTGGTACCTGTGTGAACGTGGGCTGCGTGCCGA 60
4 TTCTCGAGGATGTCATGAACAGACGCCGCATTGAACATGATCTTTTTCGGCACGCAGCCC 60
5 TGTTCATGACATCCTCGAGAACTCTCGCCACTATGGTTTTGATACGAAATTCTCCTTCAA 60
6 TGTATTTGTCACGACGTTCGACCAGCAGTGGGAGATTGAAGGAGAATTTCGTATCAAAAC 60
7 TCGAACGTCGTGACAAATACATCCAGCGTCTCAACAACATTTATCGCCAGAACCTCTCTA 60
8 AAAGACGCGGTGCCTTCGTACAGGTCAACCTTGTCTTTAGAGAGGTTCTGGCGATAAATG 60
9 GAAGGCACCGCGTCTTTCCTCTCTGAAAACCGTATTCTGATTAAAGGTACGAAAGATAAT 60
10 CCTCGTTCAGCGGACCATTGTCCTTGTTGTTATTATCTTTCGTACCTTTAATCAGAATAC 60
11 TGGTCCGCTGAACGAGGAAATCCTGGAAGGTCGTAACATCCTGATCGCGGTCGGTAACAA 60
12 CTGATGGTGTTTTCGATACCTTTTACCGGTGGGAAAACAGGTTTGTTACCGACCGCGATC 60
13 TAAAAGGTATCGAAAACACCATCAGCAGCGACGAGTTCTTCAACATCAAGGAATCCAAGA 60
14 TCGACTGCGATATAACCGCTACCAACGATACCGATTTTCTTGGATTCCTTGATGTTGAAG 60
15 GCGGTTATATCGCAGTCGAACTGATCAACGTGATCAAACGCCTCGGTATTGACTCTTACA 60
16 CGTCAAACTTACGCAGAATGCGGTTACCACGCGCGAAGATGTAAGAGTCAATACCGAGGC 60
17 GCATTCTGCGTAAGTTTGACGAGTCTGTCATCAATGTTCTGGAAAATGATATGAAGAAGA 60
18 ACAACGTCCGCGAAGGTAACGATGTTAATGTTATTCTTCTTCATATCATTTTCCAGAACA 60
19 ACCTTCGCGGACGTTGTAGAAATCAAGAAAGTCTCTGACAAAAATCTGTCTATTCACCTG 60
20 ACGTGGTCAAAGTGTTCATAGATGCGACCGTCGCTCAGGTGAATAGACAGATTTTTGTCA 60
21 TCTATGAACACTTTGACCACGTCATTTACTGCGTCGGTCGTTCCCCGGATACTGAGAATC 60
22 AGTTATTGTTCGTTTCAACGTTCAGTTTTTCGAGGTTGAGATTCTCAGTATCCGGGGAAC 60
23 TGAACGTTGAAACGAACAATAACTATATCGTGGTCGACGAGAACCAGCGTACGTCCGTAA 60
24 ACTTTTTAACCATGCAGCAGTCGCCTACCGCATAGATATTGTTTACGGACGTACGCTGGT 60
25 ACTGCTGCATGGTTAAAAAGTCTAAGGAGATCGAAGACCTGAATCTGCTCAAGCTGTACA 60
26 CGGTGACGTTCTCTTTTTTGTTCAGATACGTCTCTTCGTTGTACAGCTTGAGCAGATTCA 60
27 ACAAAAAAGAGAACGTCACCGAGGACATCTTTTACAATGTCCAGCTGACCCCAGTTGCCA 60
28 TTTTTCAGGAAGAGGCGATCCGCCAGCAGACGACCCGCGTTGATGGCAACTGGGGTCAGC 60
29 GGATCGCCTCTTCCTGAAAAAAACCCGTAAGACCAACTACAAGCTGATTCCAACCGTGAT 60
30 CTCAGACAGACCAATAGTGCCGATTGGCGGGTGGCTAAAAATCACGGTTGGAATCAGCTT 60
31 GGCACTATTGGTCTGTCTGAGGAAGCTGCGATCCAGATCTACGGTAAAGAAAACGTTAAA 60
32 AAAAGAAGAGGTTGGTGAATTTAGATTCGTAGATTTTAACGTTTTCTTTACCGTAGATCT 60
33 TCTAAATTCACCAACCTCTTCTTTTCTGTTTATGACATTGAGCCGGAGCTGAAGGAAAAG 60
34 ATGAGTTCGTCTTTGCCAACACAAACCAGCTTCAGGTAGGTCTTTTCCTTCAGCTCCGGC 60
35 TGTTGGCAAAGACGAACTCATTAAGGGTCTGCACATCATCGGTCTGAACGCCGACGAAAT 60
36 TCGTCGCGTTCATCTTGAGCGCCACGGCGAAACCTTGAACGATTTCGTCGGCGTTCAGAC 60
37 CTCAAGATGAACGCGACGAAGAAGGACTTCGATGAAACCATCCCGATCCACCCGACGGCG 60
38 TTATTTCATCCATGGCTGCAGAGTGAGGAACTCTTCTGCCGCCGTCGGGTGGAT 54
Primer design results for 'tail' primers (this is just 2 sequences):
Forward Tail Primer:
TACTTCCAATCCATGGTCTACGATCTGATTGTAAT
Reverse Tail Primer:
CTCTGCAGCCATGGATGAAATAACAGTAAAGGTGGATA
Resources:
See ProtocolTargetDiscoveryVDS.docx for moreEtiologic Risk Group Categories (for pathogens):http://www.utexas.edu/research/rsc/ibc/agent_class.html#_Toc7238334
Databases of genes/organisms:
http://www.niaid.nih.gov/Pages/default.aspx
http://eupathdb.org/eupathdb/
https://patricbrc.vbi.vt.edu/portal/portal/patric/Home
http://www.nmpdr.org/FIG/wiki/view.cgi/Main/EssentialGenes
http://tubic.tju.edu.cn/deg/
http://csgid.org/csgid/cake/pages/community_request_gateway
http://tdrtargets.org/
http://gsc.jcvi.org/status.shtml
Scientific Nomenclature page from Center for Disease Control (gene, protein names and abbreviations)
http://wwwnc.cdc.gov/eid/pages/scientific-nomenclature.htm
Gene Information:
NCBI GENE Page: http://www.ncbi.nlm.nih.gov/gene
BLAST Page: http://blast.ncbi.nlm.nih.gov/
Protein Information:
NCBI Protein Page: http://www.ncbi.nlm.nih.gov/protein
Protein Expression Website
Protein Expression Paper: SGC_ProteinProductionPurificationNatMethods2008.pdf
Primer Overlap PCR Articles
HooverLubkowski_PCRoverlapcloninggnf042.pdf
StemmerPCRoverlapGene1995.pdf
Is my target good for Virtual Screening programs?
Reynolds_THermodynamicsLigandBinding_MedChemLett2011.pdf